PLASMINOGEN  ||| S:0 E:12 ||| NNP
AND  ||| S:12 E:16 ||| CC
ANGIOSTATIN  ||| S:16 E:28 ||| NNP
LEVELS  ||| S:28 E:35 ||| NNP
IN  ||| S:35 E:38 ||| IN
FEMALE  ||| S:38 E:45 ||| NNP
BENIGN  ||| S:45 E:52 ||| NNP
BREAST  ||| S:52 E:59 ||| NNP
LESIONS  ||| S:59 E:67 ||| NNP
It  ||| S:67 E:70 ||| PRP
is  ||| S:70 E:73 ||| VBZ
known  ||| S:73 E:79 ||| VBN
that  ||| S:79 E:84 ||| IN
benign  ||| S:84 E:91 ||| JJ
breast  ||| S:91 E:98 ||| NN
tissue  ||| S:98 E:105 ||| NN
exhibit  ||| S:105 E:113 ||| NN
relatively  ||| S:113 E:124 ||| RB
low  ||| S:124 E:128 ||| JJ
angiogenic  ||| S:128 E:139 ||| JJ
capacity ||| S:139 E:147 ||| NN
.  ||| S:147 E:149 ||| .
Activation  ||| S:149 E:160 ||| NNP
of  ||| S:160 E:163 ||| IN
angiogenesis  ||| S:163 E:176 ||| NN
in  ||| S:176 E:179 ||| IN
mammary  ||| S:179 E:187 ||| JJ
pre-malignant  ||| S:187 E:201 ||| JJ
lesions  ||| S:201 E:209 ||| NNS
could  ||| S:209 E:215 ||| MD
be  ||| S:215 E:218 ||| VB
associated  ||| S:218 E:229 ||| VBN
with  ||| S:229 E:234 ||| IN
disease  ||| S:234 E:242 ||| NN
progression  ||| S:242 E:254 ||| NNS
and  ||| S:254 E:258 ||| CC
high  ||| S:258 E:263 ||| JJ
risk  ||| S:263 E:268 ||| NN
of  ||| S:268 E:271 ||| IN
transformation  ||| S:271 E:286 ||| NN
into  ||| S:286 E:291 ||| IN
the  ||| S:291 E:295 ||| DT
breast  ||| S:295 E:302 ||| NN
cancer ||| S:302 E:308 ||| NN
.  ||| S:308 E:310 ||| .
However ||| S:310 E:317 ||| RB
,  ||| S:317 E:319 ||| ,
insight  ||| S:319 E:327 ||| VBG
into  ||| S:327 E:332 ||| IN
the  ||| S:332 E:336 ||| DT
underlying  ||| S:336 E:347 ||| JJ
molecular  ||| S:347 E:357 ||| JJ
mechanisms  ||| S:357 E:368 ||| NNS
involved  ||| S:368 E:377 ||| VBN
in  ||| S:377 E:380 ||| IN
angiogenesis  ||| S:380 E:393 ||| JJ
regulation  ||| S:393 E:404 ||| NN
in  ||| S:404 E:407 ||| IN
non-cancerous  ||| S:407 E:421 ||| JJ
breast  ||| S:421 E:428 ||| NN
pathologies  ||| S:428 E:440 ||| NN
is  ||| S:440 E:443 ||| VBZ
still  ||| S:443 E:449 ||| RB
poorly  ||| S:449 E:456 ||| RB
defined ||| S:456 E:463 ||| VBN
.  ||| S:463 E:465 ||| .
The  ||| S:465 E:469 ||| DT
purpose  ||| S:469 E:477 ||| NN
of  ||| S:477 E:480 ||| IN
the  ||| S:480 E:484 ||| DT
present  ||| S:484 E:492 ||| JJ
study  ||| S:492 E:498 ||| NN
was  ||| S:498 E:502 ||| VBD
to  ||| S:502 E:505 ||| TO
determine  ||| S:505 E:515 ||| VB
levels  ||| S:515 E:522 ||| NNS
of  ||| S:522 E:525 ||| IN
plasminogen  ||| S:525 E:537 ||| NN
and  ||| S:537 E:541 ||| CC
its  ||| S:541 E:545 ||| PRP$
proteolytic  ||| S:545 E:557 ||| JJ
fragments  ||| S:557 E:567 ||| NNS
( ||| S:567 E:568 ||| -LRB-
angiostatins ||| S:568 E:580 ||| LS
)  ||| S:580 E:582 ||| -RRB-
in  ||| S:582 E:585 ||| IN
mammary  ||| S:585 E:593 ||| JJ
dysplasia  ||| S:593 E:603 ||| NNS
( ||| S:603 E:604 ||| -LRB-
mastopathy  ||| S:604 E:615 ||| NN
and  ||| S:615 E:619 ||| CC
breast  ||| S:619 E:626 ||| JJ
cyst ||| S:626 E:630 ||| NN
)  ||| S:630 E:632 ||| -RRB-
and  ||| S:632 E:636 ||| CC
benign  ||| S:636 E:643 ||| JJ
neoplasms  ||| S:643 E:653 ||| NNS
( ||| S:653 E:654 ||| -LRB-
fibroadenomas ||| S:654 E:667 ||| LS
) ||| S:667 E:668 ||| -RRB-
.  ||| S:668 E:670 ||| .
Plasminogen  ||| S:670 E:682 ||| NNP
and  ||| S:682 E:686 ||| CC
angiostatins  ||| S:686 E:699 ||| NNS
were  ||| S:699 E:704 ||| VBD
analyzed  ||| S:704 E:713 ||| VBN
using  ||| S:713 E:719 ||| VBG
immunoblotting  ||| S:719 E:734 ||| NNS
and  ||| S:734 E:738 ||| CC
quantified  ||| S:738 E:749 ||| VBN
by  ||| S:749 E:752 ||| IN
densitometric  ||| S:752 E:766 ||| JJ
scanning ||| S:766 E:774 ||| NN
.  ||| S:774 E:776 ||| .
The  ||| S:776 E:780 ||| DT
significant  ||| S:780 E:792 ||| JJ
increase  ||| S:792 E:801 ||| NN
in  ||| S:801 E:804 ||| IN
plasminogen  ||| S:804 E:816 ||| JJ
levels  ||| S:816 E:823 ||| NNS
was  ||| S:823 E:827 ||| VBD
found  ||| S:827 E:833 ||| VBN
in  ||| S:833 E:836 ||| IN
fibrocystic ||| S:836 E:847 ||| NN
,  ||| S:847 E:849 ||| ,
cysts ||| S:849 E:854 ||| NN
,  ||| S:854 E:856 ||| ,
and  ||| S:856 E:860 ||| CC
non-proliferatious  ||| S:860 E:879 ||| JJ
fibroadenoma  ||| S:879 E:892 ||| JJ
masses  ||| S:892 E:899 ||| NNS
( ||| S:899 E:900 ||| -LRB-
4.7- ||| S:900 E:904 ||| NNP
,  ||| S:904 E:906 ||| ,
3.7- ||| S:906 E:910 ||| NNP
,  ||| S:910 E:912 ||| ,
and  ||| S:912 E:916 ||| CC
3.5-fold ||| S:916 E:924 ||| NNP
,  ||| S:924 E:926 ||| ,
respectively ||| S:926 E:938 ||| RB
)  ||| S:938 E:940 ||| -RRB-
compared  ||| S:940 E:949 ||| VBN
to  ||| S:949 E:952 ||| TO
healthy  ||| S:952 E:960 ||| JJ
breast  ||| S:960 E:967 ||| NN
tissues  ||| S:967 E:975 ||| NNS
( ||| S:975 E:976 ||| -LRB-
control ||| S:976 E:983 ||| NN
) ||| S:983 E:984 ||| -RRB-
.  ||| S:984 E:986 ||| .
In  ||| S:986 E:989 ||| IN
the  ||| S:989 E:993 ||| DT
same  ||| S:993 E:998 ||| JJ
benign  ||| S:998 E:1005 ||| JJ
lesions ||| S:1005 E:1012 ||| NNS
,  ||| S:1012 E:1014 ||| ,
6.7- ||| S:1014 E:1018 ||| NNP
,  ||| S:1018 E:1020 ||| ,
4- ||| S:1020 E:1022 ||| NNP
,  ||| S:1022 E:1024 ||| ,
and  ||| S:1024 E:1028 ||| CC
3.7-fold  ||| S:1028 E:1037 ||| CD
increase  ||| S:1037 E:1046 ||| NN
in  ||| S:1046 E:1049 ||| IN
plasminogen  ||| S:1049 E:1061 ||| CD
50  ||| S:1061 E:1064 ||| CD
kDa  ||| S:1064 E:1068 ||| JJ
fragment  ||| S:1068 E:1077 ||| NN
( ||| S:1077 E:1078 ||| -LRB-
angiostatin ||| S:1078 E:1089 ||| LS
)  ||| S:1089 E:1091 ||| -RRB-
levels  ||| S:1091 E:1098 ||| NNS
as  ||| S:1098 E:1101 ||| RB
compared  ||| S:1101 E:1110 ||| VBN
with  ||| S:1110 E:1115 ||| IN
control  ||| S:1115 E:1123 ||| NN
were  ||| S:1123 E:1128 ||| VBD
also  ||| S:1128 E:1133 ||| RB
observed ||| S:1133 E:1141 ||| VBD
.  ||| S:1141 E:1143 ||| .
Activation  ||| S:1143 E:1154 ||| NNP
of  ||| S:1154 E:1157 ||| IN
matrix  ||| S:1157 E:1164 ||| CD
metalloproteinase-9 ||| S:1164 E:1183 ||| CD
,  ||| S:1183 E:1185 ||| ,
which  ||| S:1185 E:1191 ||| WDT
was  ||| S:1191 E:1195 ||| VBD
detected  ||| S:1195 E:1204 ||| VBN
using  ||| S:1204 E:1210 ||| VBG
gelatine  ||| S:1210 E:1219 ||| JJ
zymography ||| S:1219 E:1229 ||| NN
,  ||| S:1229 E:1231 ||| ,
could  ||| S:1231 E:1237 ||| MD
be  ||| S:1237 E:1240 ||| VB
responsible  ||| S:1240 E:1252 ||| JJ
for  ||| S:1252 E:1256 ||| IN
plasminogen  ||| S:1256 E:1268 ||| JJ
cleavage  ||| S:1268 E:1277 ||| NN
and  ||| S:1277 E:1281 ||| CC
abundance  ||| S:1281 E:1291 ||| NN
of  ||| S:1291 E:1294 ||| IN
angiostatin  ||| S:1294 E:1306 ||| JJ
infibrocystic  ||| S:1306 E:1320 ||| NN
and  ||| S:1320 E:1324 ||| CC
cyst  ||| S:1324 E:1329 ||| JJ
masses ||| S:1329 E:1335 ||| NNS
.  ||| S:1335 E:1337 ||| .
In  ||| S:1337 E:1340 ||| IN
contrast ||| S:1340 E:1348 ||| NN
,  ||| S:1348 E:1350 ||| ,
dramatic  ||| S:1350 E:1359 ||| JJ
decrease  ||| S:1359 E:1368 ||| NN
of  ||| S:1368 E:1371 ||| IN
both  ||| S:1371 E:1376 ||| DT
plasminogen  ||| S:1376 E:1388 ||| NN
and  ||| S:1388 E:1392 ||| CC
angiostatin  ||| S:1392 E:1404 ||| JJ
levels  ||| S:1404 E:1411 ||| NNS
( ||| S:1411 E:1412 ||| -LRB-
3.8-  ||| S:1412 E:1417 ||| NNP
and  ||| S:1417 E:1421 ||| CC
5.3-folds ||| S:1421 E:1430 ||| NNP
,  ||| S:1430 E:1432 ||| ,
respectively ||| S:1432 E:1444 ||| RB
)  ||| S:1444 E:1446 ||| -RRB-
was  ||| S:1446 E:1450 ||| VBD
shown  ||| S:1450 E:1456 ||| VBN
in  ||| S:1456 E:1459 ||| IN
tissues  ||| S:1459 E:1467 ||| NNS
of  ||| S:1467 E:1470 ||| IN
proliferatious  ||| S:1470 E:1485 ||| JJ
form  ||| S:1485 E:1490 ||| NN
of  ||| S:1490 E:1493 ||| IN
fibroadenoma  ||| S:1493 E:1506 ||| NN
in  ||| S:1506 E:1509 ||| IN
comparison  ||| S:1509 E:1520 ||| NN
with  ||| S:1520 E:1525 ||| IN
that  ||| S:1525 E:1530 ||| DT
of  ||| S:1530 E:1533 ||| IN
the  ||| S:1533 E:1537 ||| DT
dormant  ||| S:1537 E:1545 ||| JJ
type  ||| S:1545 E:1550 ||| NN
of  ||| S:1550 E:1553 ||| IN
this  ||| S:1553 E:1558 ||| DT
neoplasm ||| S:1558 E:1566 ||| NN
.  ||| S:1566 E:1568 ||| .
Based  ||| S:1568 E:1574 ||| VBN
on  ||| S:1574 E:1577 ||| IN
the  ||| S:1577 E:1581 ||| DT
obtained  ||| S:1581 E:1590 ||| JJ
results ||| S:1590 E:1597 ||| NNS
,  ||| S:1597 E:1599 ||| ,
we  ||| S:1599 E:1602 ||| PRP
concluded  ||| S:1602 E:1612 ||| VBD
that  ||| S:1612 E:1617 ||| DT
angiostatin ||| S:1617 E:1628 ||| NN
,  ||| S:1628 E:1630 ||| ,
a  ||| S:1630 E:1632 ||| DT
potent  ||| S:1632 E:1639 ||| JJ
vessel  ||| S:1639 E:1646 ||| NN
growth  ||| S:1646 E:1653 ||| NN
inhibitor  ||| S:1653 E:1663 ||| NNS
and  ||| S:1663 E:1667 ||| CC
anti-inflammatory  ||| S:1667 E:1685 ||| JJ
molecule ||| S:1685 E:1693 ||| NN
,  ||| S:1693 E:1695 ||| ,
can  ||| S:1695 E:1699 ||| MD
play  ||| S:1699 E:1704 ||| VB
a  ||| S:1704 E:1706 ||| DT
crucial  ||| S:1706 E:1714 ||| JJ
role  ||| S:1714 E:1719 ||| NN
in  ||| S:1719 E:1722 ||| IN
pathophysiology  ||| S:1722 E:1738 ||| NN
of  ||| S:1738 E:1741 ||| IN
non-cancerous  ||| S:1741 E:1755 ||| JJ
breast  ||| S:1755 E:1762 ||| NN
diseases ||| S:1762 E:1770 ||| NNS
.  ||| S:1770 E:1772 ||| .
Further  ||| S:1772 E:1780 ||| JJ
studies  ||| S:1780 E:1788 ||| NNS
are  ||| S:1788 E:1792 ||| VBP
needed  ||| S:1792 E:1799 ||| VBN
to  ||| S:1799 E:1802 ||| TO
evaluate  ||| S:1802 E:1811 ||| VB
potential  ||| S:1811 E:1821 ||| JJ
diagnostic  ||| S:1821 E:1832 ||| JJ
and  ||| S:1832 E:1836 ||| CC
clinical  ||| S:1836 E:1845 ||| JJ
implications  ||| S:1845 E:1858 ||| NNS
of  ||| S:1858 E:1861 ||| IN
these  ||| S:1861 E:1867 ||| DT
proteins  ||| S:1867 E:1876 ||| NNS
for  ||| S:1876 E:1880 ||| IN
prediction  ||| S:1880 E:1891 ||| NN
and  ||| S:1891 E:1895 ||| CC
therapy  ||| S:1895 E:1903 ||| NN
of  ||| S:1903 E:1906 ||| IN
benign  ||| S:1906 E:1913 ||| JJ
breast  ||| S:1913 E:1920 ||| NN
pathologies ||| S:1920 E:1931 ||| NN
.  ||| S:1931 E:1933 ||| .
